Literature DB >> 28450896

Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis.

Jana Lizrova Preiningerova1, Marta Vachova2.   

Abstract

Daclizumab is a humanized monoclonal antibody that binds to the α subunit (CD25) of the interleukin-2 receptor and favorably modulates the immune environment in multiple sclerosis (MS). Blockage of CD25, among other effects, causes expansion and enhanced function of regulatory CD56bright natural killer cells, which seems to be the leading mechanism of action in MS. Phase II and III clinical trials have demonstrated that monthly subcutaneous injections of daclizumab high yield process (DAC HYP) 150 mg in patients with relapsing MS led to a significant reduction of annualized relapse rate and decreased number of contrast-enhanced lesions on brain magnetic resonance imaging. Treatment with DAC HYP had efficacy superior to treatment with weekly injections of interferon β1a. This review summarizes the development of and clinical experience with daclizumab in MS.

Entities:  

Keywords:  CD25; daclizumab; interleukin 2; multiple sclerosis

Year:  2016        PMID： 28450896      PMCID： PMC5400154          DOI： 10.1177/1756285616671887

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN： 1756-2856            Impact factor:   6.570


  33 in total

Review 1.  Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.

Authors:  L R Wiseman; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 2.  The role of interleukin-2 during homeostasis and activation of the immune system.

Authors:  Onur Boyman; Jonathan Sprent
Journal:  Nat Rev Immunol       Date:  2012-02-17       Impact factor: 53.106

3.  Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.

Authors:  Lei Diao; Yaming Hang; Ahmed A Othman; Ivan Nestorov; Jonathan Q Tran
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

Review 4.  Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy.

Authors:  Wei Liao; Jian-Xin Lin; Warren J Leonard
Journal:  Immunity       Date:  2013-01-24       Impact factor: 31.745

5.  Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

Authors:  Bibiana Bielekova; Thomas Howard; Amy N Packer; Nancy Richert; Gregg Blevins; Joan Ohayon; Thomas A Waldmann; Henry F McFarland; Roland Martin
Journal:  Arch Neurol       Date:  2009-04

6.  Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

Authors:  Ralf Gold; Gavin Giovannoni; Krzysztof Selmaj; Eva Havrdova; Xavier Montalban; Ernst-Wilhelm Radue; Dusan Stefoski; Randy Robinson; Katherine Riester; Jitesh Rana; Jacob Elkins; Gilmore O'Neill
Journal:  Lancet       Date:  2013-04-04       Impact factor: 79.321

7.  Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Authors:  Ludwig Kappos; Heinz Wiendl; Krzysztof Selmaj; Douglas L Arnold; Eva Havrdova; Alexey Boyko; Michael Kaufman; John Rose; Steven Greenberg; Marianne Sweetser; Katherine Riester; Gilmore O'Neill; Jacob Elkins
Journal:  N Engl J Med       Date:  2015-10-08       Impact factor: 91.245

8.  Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.

Authors:  Bibiana Bielekova; Nancy Richert; Thomas Howard; Gregg Blevins; Silva Markovic-Plese; Jennifer McCartin; Joseph A Frank; Jens Würfel; Joan Ohayon; Thomas A Waldmann; Henry F McFarland; Roland Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-25       Impact factor: 11.205

9.  Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes.

Authors:  Christopher E Lowe; Jason D Cooper; Todd Brusko; Neil M Walker; Deborah J Smyth; Rebecca Bailey; Kirsi Bourget; Vincent Plagnol; Sarah Field; Mark Atkinson; David G Clayton; Linda S Wicker; John A Todd
Journal:  Nat Genet       Date:  2007-08-05       Impact factor: 38.330

10.  Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis.

Authors:  Jonathan Q Tran; Ahmed A Othman; Alvydas Mikulskis; Paul Wolstencroft; Jacob Elkins
Journal:  Clin Pharmacol       Date:  2016-02-11
View more
  2 in total

1.  Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination.

Authors:  Ludwig Kappos; Stanley Cohan; Douglas L Arnold; Randy R Robinson; Joan Holman; Sami Fam; Becky Parks; Shan Xiao; Wanda Castro-Borrero
Journal:  Ther Adv Neurol Disord       Date:  2021-02-26       Impact factor: 6.570

2.  IL-2 and Mycobacterial Lipoarabinomannan as Targets of Immune Responses in Multiple Sclerosis Patients.

Authors:  Marco Bo; Magdalena Niegowska; Jessica Frau; GianPietro Sechi; Giannina Arru; Eleonora Cocco; Leonardo A Sechi
Journal:  Microorganisms       Date:  2020-04-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.